There are a number of lessons oncologists have learned as the population of women who were diagnosed with breast cancer at a younger age grow older, said Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center.
There are a number of lessons oncologists have learned as the population of women who were diagnosed with breast cancer at a younger age grow older, said Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center.
Transcript (slightly modified)
What updates have there been for the management of breast cancer in older women who were diagnosed at an early age?
We have a growing population of women who were diagnosed with breast cancer at a younger age and then have been followed for many years after their initial diagnosis of breast cancer, and there are a couple of things that we have to pay attention to there.
First of all, we know that in the estrogen-receptor (ER)-positive group of breast cancer patients that delayed recurrence occurs. So over half of the recurrences in ER-positive breast cancer actually occur after 5 years. So one of the things we’re paying attention to now, as women age, is additional adjuvant-endocrine therapy, including 10 years of therapy. And there is data to support giving 5 years of an aromatase inhibitor after 5 years of tamoxifen.
In fact, actually the women who are receiving tamoxifen premenopausal who then become postmenopausal seem to be the group that derives the most benefit 10-15 years later from the additional 5 years of adjuvant therapy.
We don’t have a lot of data about screening in women who have had breast cancer at older ages. In general, the guideline recommendation for an average risk woman is to stop screening in the mid-70s. In my own practice though, patients who have had breast cancer at any age continue to go through screening even when they get into older age groups because we know that there is an increased risk of a second breast cancer after a woman has had a first breast cancer.
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
May 1st 2024The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.
Read More